Key clinical point: Baricitinib therapy resulted in clinically meaningful improvement in itch severity leading to significantly better quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: By week 16, higher proportion of patients receiving baricitinib 2 mg (25.2%; P less than .0001 ) and 1 mg (15.9%; P = .0114) vs placebo (5.7%) experienced improvements in itch severity. Higher proportion of patients with vs without itch improvement showed no impact of AD on QoL (P less than .0001).
Study details: Findings are from a post hoc analysis of phase 3 trial, BREEZE-AD5 involving 440 adults with moderate-to-severe AD who received baricitinib 1 mg, 2 mg, or placebo once daily.
Disclosures: This work was funded by Eli Lilly and Company. Some of the authors declared receiving grants, funding, consulting fees, and/or honoraria from and/or serving as board member, speaker, advisor, and/or investigator for various sources including Eli Lilly. Five of the authors declared being employees and shareholders of Eli Lilly.
Source: Lio PA et al. J Dermatolog Treat. 2021 Jun 28. doi: 10.1080/09546634.2021.1914308 .